/PRNewswire/ The Board of Directors of Calliditas Therapeutics AB (publ) today resolved to carry out a new issue of 5,908,018 C-shares and to subsequently.
/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products for.
STOCKHOLM, May 19, 2022 /PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the Committee for Medicinal Products for Human
/PRNewswire/ Start of TARPEYO™ Commercial Launch in the US "During the first quarter Calliditas launched its first commercial product, TARPEYO, in the US,.
/PRNewswire/ Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been randomized.